Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yttrium-86 is a positron-emitting radioisotope of yttrium with a half-life of approximately 14.74 hours, making it suitable for Positron Emission Tomography (PET) imaging. It is primarily utilized as a diagnostic surrogate for the therapeutic isotope yttrium-90 (Y-90). Because yttrium-86 and yttrium-90 are chemically identical, Y-86 labeled compounds (such as monoclonal antibodies or peptides) can be used to accurately predict the biodistribution and radiation dosimetry of Y-90 therapies, a concept central to the field of theranostics. It is typically produced in a cyclotron via the (p,n) nuclear reaction on enriched strontium-86 targets. Clinical applications often involve its conjugation to targeting vectors like DOTATOC or various antibodies to visualize target expression and estimate therapeutic window before administering the higher-energy beta-emitting Y-90 counterpart.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yttrium-86.